Weight gain in men in their 40s and 50s is one of the most common health concerns in clinical practice, and one of the most frequently misunderstood. The standard narrative — eat less, move more — is not wrong exactly, but it is incomplete. For many men in this age group, the weight that has accumulated is not primarily the result of changed eating habits or reduced activity. It is the result of changed physiology.
GLP-1 receptor agonists — a class of medications that includes semaglutide and tirzepatide — have substantially changed what medical weight management can achieve. But understanding what they do, and what they do not do, requires some understanding of why weight accumulates in men in the first place.
Why weight gain in men is not simply a calorie problem
From the late 30s onward, testosterone in men declines gradually. Testosterone plays a central role in body composition: it supports lean muscle mass, inhibits fat accumulation, and influences where fat is deposited. As testosterone falls, the balance shifts — muscle is harder to maintain and fat, particularly visceral fat around the abdomen, accumulates more readily.
The relationship between testosterone and visceral fat runs in both directions. Excess visceral fat converts testosterone to oestrogen through a process called peripheral aromatisation, suppressing the hypothalamic-pituitary-gonadal axis and driving testosterone lower still. Low testosterone promotes further fat gain; fat gain further lowers testosterone. This cycle, sometimes termed obesity-related functional hypogonadism, is now well-characterised in the literature.[1] Clinically significant weight loss substantially reverses it.[1]
Insulin resistance compounds the picture. Visceral fat is metabolically active in ways that subcutaneous fat is not — it drives systemic inflammation, impairs insulin signalling, and promotes further deposition of ectopic fat in the liver and muscle. Poor sleep — common in men in this age group — elevates cortisol, which directly promotes fat accumulation and worsens insulin resistance. These are physiological drivers, not motivational failures.
This is the metabolic context in which GLP-1 medications work. They are effective precisely because they address the hormonal signalling that drives hunger and fat accumulation — not because they impose restriction from the outside.
What GLP-1 receptor agonists actually do
GLP-1 (glucagon-like peptide-1) is a hormone released from the gut in response to eating. It signals satiety to the brain, slows gastric emptying so that fullness lasts longer, and stimulates insulin release in proportion to blood glucose levels. GLP-1 receptor agonists mimic this hormone at pharmacological doses, producing a sustained reduction in appetite and caloric intake — not through willpower, but through direct hormonal signalling.
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist, targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is a related incretin hormone with complementary effects on appetite regulation and fat metabolism. The addition of GIP action appears to enhance both the weight loss and metabolic effects compared to GLP-1 agonism alone.
The evidence — including the first head-to-head trial
The efficacy of both agents is now established across large, well-designed randomised controlled trials.
The STEP 1 trial, published in the New England Journal of Medicine in 2021, evaluated once-weekly semaglutide 2.4 mg in 1,961 adults with obesity without diabetes. At 68 weeks, participants assigned to semaglutide achieved a mean weight loss of 14.9%, compared with 2.4% with placebo.[2] 86% of participants in the semaglutide group achieved at least 5% weight loss.[2]
The SURMOUNT-1 trial, published in 2022, evaluated tirzepatide in 2,539 adults with obesity. At 72 weeks, mean weight loss was 16.0%, 21.4%, and 22.5% at 5 mg, 10 mg, and 15 mg doses respectively, compared with 2.4% with placebo.[3] Importantly, fat mass was reduced approximately three times more than lean mass — a ratio with particular relevance for men concerned about muscle preservation.[3]
The SURMOUNT-5 trial, published in the New England Journal of Medicine in May 2025, provided the first direct head-to-head comparison of the two agents. 751 adults with obesity were randomised to the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide 2.4 mg. At 72 weeks, tirzepatide produced a mean weight loss of 20.2%, compared with 13.7% for semaglutide — a statistically significant and clinically meaningful difference.[4] Both agents were effective; tirzepatide produced approximately 47% more weight loss from baseline.
One finding in SURMOUNT-5 is directly relevant to men: weight loss was approximately 6% lower in men than in women in both treatment groups.[4] The trial enrolled a higher proportion of men (35%) than most obesity trials, which may partly explain why mean weight loss was slightly lower than in previous semaglutide and tirzepatide trials. Men and women respond to these medications — the response is simply not identical. This is worth knowing before starting, and it argues for realistic individual targets rather than comparison with trial averages.
The muscle mass question
One of the most common concerns men raise about GLP-1 medications is muscle loss. It is a legitimate question. Any substantial weight loss — dietary, surgical, or pharmacological — involves some reduction in lean mass alongside fat. For men, who carry more absolute lean mass and whose long-term metabolic and functional health depends partly on maintaining it, this deserves an honest answer rather than reassurance.
The honest answer is that these medications reduce fat substantially more than lean mass. In SURMOUNT-1, fat mass was reduced by 33.9% compared with a 10.9% reduction in lean mass in the tirzepatide group.3 The ratio is favourable, but lean mass reduction is real and meaningful at the absolute amounts of weight lost in these trials.
The practical implication is straightforward: resistance training and adequate dietary protein are not optional extras when using these medications. They are the clinical countermeasure to lean mass reduction. A well-managed programme accounts for this from the outset — not as an afterthought once muscle loss has already occurred.
The testosterone connection
For men with obesity-related functional hypogonadism — low testosterone driven by excess visceral fat rather than by a primary testicular or pituitary disorder — clinically significant weight loss tends to improve testosterone substantially. A 2025 paper in the Journal of Clinical Endocrinology and Metabolism by Muir, Wittert and Handelsman documents this clearly: weight loss achieved through diet, exercise, or bariatric surgery produces increases in testosterone proportionate to the degree of weight lost, and these increases are often sufficient to resolve the symptoms attributed to low testosterone without requiring testosterone replacement therapy.[1]
This has direct implications for how weight loss should be managed in men who also present with low testosterone and its associated symptoms — fatigue, reduced libido, mood changes, reduced muscle mass. The conventional response has been to treat the testosterone. The more metabolically complete response is to treat the obesity, which addresses the testosterone indirectly but often more durably.
Whether testosterone replacement is also appropriate — in addition to, or instead of, weight management — is a clinical judgement that requires distinguishing functional hypogonadism from pathological hypogonadism. These are different conditions with different treatments, and the distinction matters. A proper metabolic and hormonal assessment before starting any treatment is how that distinction is made.
What these medications do not fix on their own
GLP-1 medications act primarily on appetite and insulin signalling. They are not a comprehensive metabolic reset. They do not directly address chronic sleep disruption elevating cortisol, insulin resistance from long-standing dietary patterns, or the hormonal drivers that are contributing to weight accumulation alongside the caloric surplus.
A well-structured programme assesses these alongside medication. Body composition, insulin and glucose handling, hormonal status, sleep, and the specific pattern of fat distribution all inform both the treatment plan and the realistic expectations for it. The medication does the heavy work on appetite; the broader assessment determines whether other interventions are also needed.
If weight loss has not responded to the approaches you have already tried, that is a reason to speak to a doctor – not a reason to try harder alone.
The maintenance question — addressed honestly
When GLP-1 medications are stopped, weight is typically regained. This is now well-documented. The STEP 1 trial extension followed participants for one year after semaglutide was discontinued. Participants who stopped the medication regained approximately two-thirds of the weight lost during treatment within twelve months, and the cardiometabolic improvements gained during treatment largely reversed.[5] Worse still, while on the medication both muscle and fat are lost (albeit at a healthy level) but during the rebound almost all the weight put back on is fat.
This is not a failure of the medication. It reflects that obesity involves persistent hormonal dysregulation of appetite — when the pharmacological correction is removed, the underlying biology reasserts itself. It is the same reason that antihypertensive medications need to be continued to maintain blood pressure control.
The practical consequence is that maintenance needs to be planned from the beginning, not addressed when treatment ends. Options include lower-dose continuation, structured tapering, and the lifestyle foundations — resistance training, dietary protein, sleep — that support whatever pharmacological approach is taken. None of this is complicated, but it requires that the conversation about stopping is had at the start, not the end.
GLP-1 medications represent a genuine advance in what medical weight management can achieve. For men in their 40s and 50s dealing with visceral weight gain that has not responded to standard approaches, the evidence is now substantial and the options are real. The consultation that determines which agent, at what dose, for which patient, and alongside what else — is where that evidence gets applied to an individual.
Stopping a GLP-1 medication without a plan is one of the most common reasons the weight comes back. That plan is worth building with a doctor from the start, not working out afterwards. Speak to a doctor before starting any GLP-1 medication.
- Muir CA, Wittert GA, Handelsman DJ. Approach to the patient: low testosterone concentrations in men with obesity. Journal of Clinical Endocrinology and Metabolism. 2025;110(9):e3125–e3130. doi:10.1210/clinem/dgaf137. PMID: 40052430.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183. PMID: 33567185.
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038. PMID: 35658024.
- Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine. 2025;393(1):26–36. doi:10.1056/NEJMoa2416394. PMID: 40353578. Published online May 11, 2025.
- Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553–1564. doi:10.1111/dom.14725. PMID: 35441470.